Navigation Links
NYU-Poly Professor Among First Winners of BioAccelerate NYC Prize; Project May Move Diagnostic Medicine from the Lab to the Palm of a Hand
Date:5/3/2010

NEW YORK, May 3 /PRNewswire/ -- The future of diagnostic medicine may lie in an inexpensive credit card-sized device that requires no advanced training to operate, uses minimal power and provides high-accuracy detection of infectious diseases from a single patient sample in less than 30 minutes.

Dr. Kalle Levon, professor of chemical and biological science at Polytechnic Institute of New York University (NYU-Poly), is one critical step closer to turning this concept into reality as one of six winners of the first BioAccelerate NYC Prize, a $1.5 million grant created to fuel the growth of life science and biotech businesses in New York City.

Each BioAccelerate NYC winner will receive a $250,000 grant to conduct late-stage, proof-of-concept research on products to improve health and wellness. BioAccelerate NYC is a project of the Partnership for New York City and the New York City Economic Development Corporation (NYCEDC).

Dr. Levon's proposal -- the sole winner to address a diagnostic issue -- tackles the inefficiencies of infectious disease diagnostics including high cost, lengthy result times, bulky equipment and the need for large sample sizes and highly trained personnel.  

Uniting experts in polymer chemistry, electrical engineering and medical research, Dr. Levon has conceptualized a handheld, point-of-care device to detect infectious diseases using a patented floating gate field effect transistor (FGFET) biosensor.

This cost-effective biosensor utilizes readily available MOS transistors coated with a conductive polymer. When in contact with a small sample of body fluid, the polymer detects biological and chemical binding reactions with a high degree of sensitivity, translating these signals into electrical signals. A light on the device would indicate a positive or negative test result.  Due to small size, easy interpretation of results and low sample volume required, a technician with basic training could utilize the device in any clinical setting, no matter how rudimentary, anywhere in the world.

This field of study, known as organic electronics, has been applied to diagnostic techniques in research and academia for a decade, but Dr. Levon's team is the first to conceive a commercial application utilizing this technology.

"Our goal at NYU-Poly is to transform research outcomes into applications that solve 21st century problems," said NYU-Poly Provost Dr. Dianne Rekow. "Dr. Levon's work is an ideal example of our core philosophy, i-squared-e -- invention, innovation and entrepreneurship -- come to life. We salute the city for its support of a project that could benefit healthcare systems worldwide."

The BioAccelerate grant will facilitate the development of a complete prototype, created in partnership with The Brooklyn Hospital. The pilot will focus on chlamydia and gonorrhea detection, but the technique could be applied to any infectious disease, including H1N1 or HIV.

Previous lab tests proved the FGFET biosensor's efficacy in detecting a single biomarker, but Dr. Levon 's vision includes the creation of a scalable, multiplex array of sensors capable of testing for several agents simultaneously, as well as applications for cancer diagnostics.  

About Polytechnic Institute of New York University

Polytechnic Institute of New York University (formerly Polytechnic University), an affiliate of New York University, is one of New York City's most comprehensive schools of engineering, applied sciences, technology, and research, and is rooted in a 156-year tradition of invention, innovation, and entrepreneurship: i-squared-e.

The institution, founded in 1854, is one of the nation's oldest private engineering schools. In addition to its main campus at MetroTech Center in downtown Brooklyn, it offers programs at sites throughout the region and around the globe. NYU-Poly has centers in Long Island, Manhattan and Westchester County; globally, it has programs in Israel, China and will be an integral part of NYU's campus in Abu Dhabi opening in autumn 2010.

For more information, visit www.poly.edu.

Downloadable photo at http://www.poly.edu/about/press/releases


'/>"/>
SOURCE Polytechnic Institute of New York University
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
2. Professor Riccardo Lencioni Joins Delcath Systems Scientific Advisory Board
3. KGI Professor Ian Phillips Awarded Defense Grants for Medical Combat Research
4. Limited Healthcare Infrastructure and Weak Intellectual Property Protection are Among the Challenges Pharma Faces with Emerging Market Expansion
5. New Study Links dLife to Increased Rx Drug Usage Among Diabetes Consumers
6. Carefx Portal Solution to Deliver First Time, Statewide Access to Patient Data Among Hospitals in the LSU Network
7. Native Remedies NutraRx Brand of Natural Products for Medical Practitioners Among First to Earn Prestigious Emerson EQP Seal
8. Aurora Hospitals Named Among the Nations Best
9. A Drugs Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections
10. At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease
11. The Scientist Magazine Recognizes febits HybSelect(TM) Among the Winners of Top 10 Innovations of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
(Date:2/8/2016)... February 8, 2016 ... published by Allied Market Research titled, "World ... Forecasts, 2014-2020", estimates the world synthetic biology market ... and sequencing technology segment would continue to lead ... tools segment, collectively, held around half of the ...
(Date:2/8/2016)... HOUSTON , 8. Februar 2016 /PRNewswire/ ... veröffentlichte heute eine Infografik mit dem Titel ... ganzen Welt), mit der der Krankheit gegenüber ... die dazu ermutigen soll, Medikamentenresistenz bei Epilepsie ... der allgemeinen Diskussion zu machen. Mithilfe der ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... expansion into Canada to provide its range of unique and advantaged protective ... Quebec City that will provide bilingual customer service and marketing support. A new ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... The schedule ... in this country. The AutismOne 2016 Conference, which is being held May 25-29 at ... won’t hear elsewhere about helpful interventions and causes of chronic illness in children. , ...
Breaking Medicine News(10 mins):